



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Kevin J. Tracey and Haichao Wang

Application No.: 10/719,150 Group: 3754

Filed: November 21, 2003 Examiner: Not Yet Assigned

Confirmation No.: 3380

For: ANTAGONISTS OF HMG1 FOR TREATING INFLAMMATORY CONDITIONS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

6/21/04 Carol M. Bowerman

Date Signature

Carol M. Bowerman

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- [ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references (AT4-AZ4 and AR5-AU5) are enclosed.

[ ] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

[ ] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

[ ] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

[ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

[ ] the enclosed English language abstract.

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ Examiner

\_\_\_\_ Date

[ ] A copy of each above-cited application, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By David E. Brook  
David E. Brook  
Registration No.: 22,592  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 6/2/04

PTO-1449 REPRODUCED <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> June 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3268.1000-012	APPLICATION NO. 10/719,150
	FIRST NAMED INVENTOR Kevin J. Tracey	FILING DATE November 21, 2003
	EXAMINER	CONFIRMATION NO. 3380
		GROUP 3754

*O I P E SC189*  
JUN 04 2004  
PATENT & TRADEMARK OFFICE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AT4	Passalacqua, M., <i>et al.</i> , "Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation," <i>Neuroscience</i> , 82(4):1021-1028 (1998).
AU4	Chou, D. K. H., <i>et al.</i> , "Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain," <i>J. Neurochem.</i> , 77:120-131 (2001).
AV4	Imamura, T., <i>et al.</i> , "Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein," <i>J. Biol. Chem.</i> , 276(10):7534-7540 (2001).
AW4	Ise, T., <i>et al.</i> , "Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen," <i>Cancer Res.</i> , 59:342-346 (1999).
AX4	Jung, F., <i>et al.</i> , "Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis," <i>Arthritis Rheum.</i> , 40(10):1803-1809 (1997).
AY4	Bianchi, M. E., <i>et al.</i> , "Specific Recognition of Cruciform DNA by Nuclear Protein HMG1," <i>Science</i> , 243:1056-1059 (1989).
AZ4	Suda, T., <i>et al.</i> , "A Novel Activity of HMG Domains: Promotion of the Triple-Stranded Complex Formation Between DNA Containing (GGA/TCC) <sub>11</sub> and d(GGA) <sub>11</sub> Oligonucleotides," <i>Nucleic Acids Res.</i> , 24(23):4733-4740 (1996).
AR5	Ayer, L. M., <i>et al.</i> , "Antibodies to HMG Proteins in Patients With Drug-Induced Autoimmunity," <i>Arthritis Rheum.</i> , 37(1):98-103 (1994).
AS5	Rauvala, H., <i>et al.</i> , "The Adhesive and Neurite-Promoting Molecule p30: Analysis of the Amino-Terminal Sequence and Production of Antipeptide Antibodies That Detect p30 at the Surface of Neuroblastoma Cells and of Brain Neurons," <i>J. Cell Biol.</i> , 107(6):2293-2305 (1988).
AT5	Sobajima, J., <i>et al.</i> , "Prevalence and Characterization of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) Directed Against HMG1 and HMG2 in Ulcerative Colitis (UC)," <i>Clin. Exp. Immunol.</i> , 111:402-407 (1998).
AU5	Yamada, S., <i>et al.</i> , "High Mobility Group Protein 1 (HMGB1) Quantified by ELISA With a Monoclonal Antibody That Does Not Cross-React With HMGB2," <i>Clin. Chem.</i> , 49(9):1535-1537 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------